(Q44084317)

29 November 2017

title

Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation (English)

1 reference

29 November 2017

1 reference

12

Ernesto T A Marques

1 reference

29 November 2017

Margherita Rosati

1

1 reference

29 November 2017

Antonio Valentin

2

1 reference

29 November 2017

Rashmi Jalah

3

1 reference

29 November 2017

Vainav Patel

4

1 reference

29 November 2017

Agneta von Gegerfelt

5

1 reference

29 November 2017

Cristina Bergamaschi

6

1 reference

29 November 2017

Candido Alicea

7

1 reference

29 November 2017

Deborah Weiss

8

1 reference

29 November 2017

Jim Treece

9

1 reference

29 November 2017

Ranajit Pal

10

1 reference

29 November 2017

Phillip D Markham

11

1 reference

29 November 2017

J Thomas August

13

1 reference

29 November 2017

Amir Khan

14

1 reference

29 November 2017

Ruxandra Draghia-Akli

15

1 reference

29 November 2017

Barbara K Felber

16

1 reference

29 November 2017

George N Pavlakis

17

1 reference

29 November 2017

language of work or name

English

0 references

publication date

21 April 2008

1 reference

29 November 2017

number of pages

7

1 reference

inferred from page(s)

published in

Vaccine

1 reference

29 November 2017

volume

26

1 reference

29 November 2017

issue

40

1 reference

29 November 2017

page(s)

5223-5229

1 reference

describes a project that uses

29 November 2017

1 reference

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Vaccine delivery methods using viral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

HIV vaccines: new frontiers in vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

A review of vaccine research and development: the human immunodeficiency virus (HIV).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

DNA vaccines for HIV: challenges and opportunities.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

DNA vaccines: recent developments and future possibilities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Cytokine-adjuvanted HIV-DNA vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Combination DNA plus protein HIV vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Current advances and challenges in HIV-1 vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

HIV-1 vaccine development: progress and prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Gene transfer into muscle by electroporation in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Increased DNA vaccine delivery and immunogenicity by electroporation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Electropermeabilization of skeletal muscle enhances gene transfer in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Efficient systemic expression of bioactive IL-15 in mice upon delivery of optimized DNA expression plasmids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Characterization of a new class of DNA delivery complexes formed by the local anesthetic bupivacaine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene Inserts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.090

7 January 2021

inferred from DOI database lookup

Prime-boost strategies in DNA vaccines.

1 reference

12 December 2020

Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA.

1 reference

12 December 2020

Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein

1 reference

12 December 2020

Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation

1 reference

12 December 2020

10.1016/J.VACCINE.2008.03.090

Identifiers

DOI

1 reference

29 November 2017

0 references

1 reference